http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 02 Jun 2026 07:29:26 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/Eikon+Therapeutics+%28EIKN%29+Reiterated+at+Overweight+by+Cantor+Fitzgerald+/26587437.html <p>Cantor Fitzgerald analyst Imogen Mansfield reiterated an Overweight rating on Eikon Therapeutics Inc. (NASDAQ: EIKN).</p><p>The analyst commented, "We think EIKN's PARP1 inhibitors have best-in-class potential and could meaningfully grow the size of the "PARP pie," offering earlier-line combinability and expansion into BRCAwt patients. We estimate product launch for EIK1003/4 in 2031 with >$1.5B peak sales across indications, and continue to assume a 60% POS for this program. We see EIK1001 as a high risk/high reward opportunity. Data from early clinical studies and the Ph2 NSCLC cohort provide signs of encouragement, but conclusive evidence of superiority over control arms (pembro/chemo in http://www.streetinsider.com/Analyst+Comments/Eikon+Therapeutics+%28EIKN%29+Reiterated+at+Overweight+by+Cantor+Fitzgerald+/26587437.html Tue, 02 Jun 2026 07:29:26 -0400 EIKN http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+Presents+Data+on+Clinical-Stage+Programs+at+the+2026+Annual+Meeting+of+the+American+Society+of+Clinical+Oncology/26577260.html <ul type="disc"><li style="margin-bottom:12pt;"><em>TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated rates of response and disease control, strengthening the case for continued development</em></li><li style="margin-bottom:12pt;"><em>Phase 1/2 trial of EIK1003 reports updated safety and efficacy monotherapy data and initial combination data with weekly paclitaxel in patients with advanced solid tumors</em></li></ul> <p>MILLBRAE, Calif., May 30, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced presentations http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+Presents+Data+on+Clinical-Stage+Programs+at+the+2026+Annual+Meeting+of+the+American+Society+of+Clinical+Oncology/26577260.html Sat, 30 May 2026 14:30:00 -0400 A.50216614 A.50216726 EIKN O.21612337 O.49773468 http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+Presents+Data+on+Clinical-Stage+Programs+at+the+2026+Annual+Meeting+of+the+American+Society+of+Clinical+Oncology/26577260.html <ul type="disc"><li style="margin-bottom:12pt;"><em>TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated rates of response and disease control, strengthening the case for continued development</em></li><li style="margin-bottom:12pt;"><em>Phase 1/2 trial of EIK1003 reports updated safety and efficacy monotherapy data and initial combination data with weekly paclitaxel in patients with advanced solid tumors</em></li></ul> <p>MILLBRAE, Calif., May 30, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced presentations http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+Presents+Data+on+Clinical-Stage+Programs+at+the+2026+Annual+Meeting+of+the+American+Society+of+Clinical+Oncology/26577260.html Sat, 30 May 2026 14:30:00 -0400 A.50216614 A.50216726 EIKN O.21612337 O.49773468 http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+Presents+Data+on+Clinical-Stage+Programs+at+the+2026+Annual+Meeting+of+the+American+Society+of+Clinical+Oncology/26577260.html <ul type="disc"><li style="margin-bottom:12pt;"><em>TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated rates of response and disease control, strengthening the case for continued development</em></li><li style="margin-bottom:12pt;"><em>Phase 1/2 trial of EIK1003 reports updated safety and efficacy monotherapy data and initial combination data with weekly paclitaxel in patients with advanced solid tumors</em></li></ul> <p>MILLBRAE, Calif., May 30, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced presentations http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+Presents+Data+on+Clinical-Stage+Programs+at+the+2026+Annual+Meeting+of+the+American+Society+of+Clinical+Oncology/26577260.html Sat, 30 May 2026 14:30:00 -0400 A.50216614 A.50216726 EIKN O.21612337 O.49773468 http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+Presents+Data+on+Clinical-Stage+Programs+at+the+2026+Annual+Meeting+of+the+American+Society+of+Clinical+Oncology/26577260.html <ul type="disc"><li style="margin-bottom:12pt;"><em>TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated rates of response and disease control, strengthening the case for continued development</em></li><li style="margin-bottom:12pt;"><em>Phase 1/2 trial of EIK1003 reports updated safety and efficacy monotherapy data and initial combination data with weekly paclitaxel in patients with advanced solid tumors</em></li></ul> <p>MILLBRAE, Calif., May 30, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced presentations http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+Presents+Data+on+Clinical-Stage+Programs+at+the+2026+Annual+Meeting+of+the+American+Society+of+Clinical+Oncology/26577260.html Sat, 30 May 2026 14:30:00 -0400 A.50216614 A.50216726 EIKN O.21612337 O.49773468 http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+Presents+Data+on+Clinical-Stage+Programs+at+the+2026+Annual+Meeting+of+the+American+Society+of+Clinical+Oncology/26577260.html <ul type="disc"><li style="margin-bottom:12pt;"><em>TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated rates of response and disease control, strengthening the case for continued development</em></li><li style="margin-bottom:12pt;"><em>Phase 1/2 trial of EIK1003 reports updated safety and efficacy monotherapy data and initial combination data with weekly paclitaxel in patients with advanced solid tumors</em></li></ul> <p>MILLBRAE, Calif., May 30, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced presentations http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+Presents+Data+on+Clinical-Stage+Programs+at+the+2026+Annual+Meeting+of+the+American+Society+of+Clinical+Oncology/26577260.html Sat, 30 May 2026 14:30:00 -0400 A.50216614 A.50216726 EIKN O.21612337 O.49773468 http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+Presents+Data+on+Clinical-Stage+Programs+at+the+2026+Annual+Meeting+of+the+American+Society+of+Clinical+Oncology/26577260.html <ul type="disc"><li style="margin-bottom:12pt;"><em>TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated rates of response and disease control, strengthening the case for continued development</em></li><li style="margin-bottom:12pt;"><em>Phase 1/2 trial of EIK1003 reports updated safety and efficacy monotherapy data and initial combination data with weekly paclitaxel in patients with advanced solid tumors</em></li></ul> <p>MILLBRAE, Calif., May 30, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced presentations http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+Presents+Data+on+Clinical-Stage+Programs+at+the+2026+Annual+Meeting+of+the+American+Society+of+Clinical+Oncology/26577260.html Sat, 30 May 2026 14:30:00 -0400 A.50216614 A.50216726 EIKN O.21612337 O.49773468 http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+Presents+Data+on+Clinical-Stage+Programs+at+the+2026+Annual+Meeting+of+the+American+Society+of+Clinical+Oncology/26577260.html <ul type="disc"><li style="margin-bottom:12pt;"><em>TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated rates of response and disease control, strengthening the case for continued development</em></li><li style="margin-bottom:12pt;"><em>Phase 1/2 trial of EIK1003 reports updated safety and efficacy monotherapy data and initial combination data with weekly paclitaxel in patients with advanced solid tumors</em></li></ul> <p>MILLBRAE, Calif., May 30, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced presentations http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+Presents+Data+on+Clinical-Stage+Programs+at+the+2026+Annual+Meeting+of+the+American+Society+of+Clinical+Oncology/26577260.html Sat, 30 May 2026 14:30:00 -0400 A.50216614 A.50216726 EIKN O.21612337 O.49773468 http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+Presents+Data+on+Clinical-Stage+Programs+at+the+2026+Annual+Meeting+of+the+American+Society+of+Clinical+Oncology/26577260.html <ul type="disc"><li style="margin-bottom:12pt;"><em>TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated rates of response and disease control, strengthening the case for continued development</em></li><li style="margin-bottom:12pt;"><em>Phase 1/2 trial of EIK1003 reports updated safety and efficacy monotherapy data and initial combination data with weekly paclitaxel in patients with advanced solid tumors</em></li></ul> <p>MILLBRAE, Calif., May 30, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced presentations http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+Presents+Data+on+Clinical-Stage+Programs+at+the+2026+Annual+Meeting+of+the+American+Society+of+Clinical+Oncology/26577260.html Sat, 30 May 2026 14:30:00 -0400 A.50216614 A.50216726 EIKN O.21612337 O.49773468 http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+Presents+Data+on+Clinical-Stage+Programs+at+the+2026+Annual+Meeting+of+the+American+Society+of+Clinical+Oncology/26577260.html <ul type="disc"><li style="margin-bottom:12pt;"><em>TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated rates of response and disease control, strengthening the case for continued development</em></li><li style="margin-bottom:12pt;"><em>Phase 1/2 trial of EIK1003 reports updated safety and efficacy monotherapy data and initial combination data with weekly paclitaxel in patients with advanced solid tumors</em></li></ul> <p>MILLBRAE, Calif., May 30, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced presentations http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+Presents+Data+on+Clinical-Stage+Programs+at+the+2026+Annual+Meeting+of+the+American+Society+of+Clinical+Oncology/26577260.html Sat, 30 May 2026 14:30:00 -0400 A.50216614 A.50216726 EIKN O.21612337 O.49773468 http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+Presents+Data+on+Clinical-Stage+Programs+at+the+2026+Annual+Meeting+of+the+American+Society+of+Clinical+Oncology/26577260.html <ul type="disc"><li style="margin-bottom:12pt;"><em>TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated rates of response and disease control, strengthening the case for continued development</em></li><li style="margin-bottom:12pt;"><em>Phase 1/2 trial of EIK1003 reports updated safety and efficacy monotherapy data and initial combination data with weekly paclitaxel in patients with advanced solid tumors</em></li></ul> <p>MILLBRAE, Calif., May 30, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced presentations http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+Presents+Data+on+Clinical-Stage+Programs+at+the+2026+Annual+Meeting+of+the+American+Society+of+Clinical+Oncology/26577260.html Sat, 30 May 2026 14:30:00 -0400 A.50216614 A.50216726 EIKN O.21612337 O.49773468 http://www.streetinsider.com/Corporate+News/Eikon+Therapeutics+to+present+six+abstracts+at+2026+ASCO+meeting/26536639.html <p>Eikon Therapeutics, Inc. (NASDAQ: EIKN) announced that six abstracts from its clinical programs will be presented at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago starting May 29, 2026.</p><p>The presentations will cover data from three drug candidates in the company's oncology pipeline. Three abstracts will focus on EIK1001, a TLR7 and TLR8 dual-agonist being tested in non-small cell lung cancer and advanced melanoma trials. The presentations include results from the Phase 2 TeLuRide-005 trial combining EIK1001 with standard first-line therapy in stage 4 non-small cell lung cancer, and data from two additional studies evaluating the drug in http://www.streetinsider.com/Corporate+News/Eikon+Therapeutics+to+present+six+abstracts+at+2026+ASCO+meeting/26536639.html Thu, 21 May 2026 17:05:25 -0400 EIKN http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+Announces+Availability+of+Six+Abstracts+for+Presentation+at+the+2026+Annual+Meeting+of+the+American+Society+of+Clinical+Oncology/26536613.html <ul><li><em>Presentations to cover progress across Eikon’s most advanced clinical-stage programs</em></li><li><em>Updated data will include those derived from trials of EIK1001, for the treatment of patients with non-small cell lung cancer (“NSCLC”), EIK1003, as a monotherapy or in combination in the treatment of patients with breast, ovarian, prostate, or pancreatic cancer, and EIK1005, which is designed to improve treatment of patients whose tumors demonstrate certain DNA replication abnormalities.</em></li></ul> <p>MILLBRAE, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+Announces+Availability+of+Six+Abstracts+for+Presentation+at+the+2026+Annual+Meeting+of+the+American+Society+of+Clinical+Oncology/26536613.html Thu, 21 May 2026 17:05:00 -0400 EIKN http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+Announces+Availability+of+Six+Abstracts+for+Presentation+at+the+2026+Annual+Meeting+of+the+American+Society+of+Clinical+Oncology/26536613.html <ul><li><em>Presentations to cover progress across Eikon’s most advanced clinical-stage programs</em></li><li><em>Updated data will include those derived from trials of EIK1001, for the treatment of patients with non-small cell lung cancer (“NSCLC”), EIK1003, as a monotherapy or in combination in the treatment of patients with breast, ovarian, prostate, or pancreatic cancer, and EIK1005, which is designed to improve treatment of patients whose tumors demonstrate certain DNA replication abnormalities.</em></li></ul> <p>MILLBRAE, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+Announces+Availability+of+Six+Abstracts+for+Presentation+at+the+2026+Annual+Meeting+of+the+American+Society+of+Clinical+Oncology/26536613.html Thu, 21 May 2026 17:05:00 -0400 EIKN http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+Updates/26468713.html <ul><li style="text-align:left;"><em>Maintained strong financial position with $596 million in cash, cash equivalents and marketable securities as of March 31, 2026</em><br/><br/></li><li style="text-align:left;"><em>Continued execution across the oncology pipeline, with a strategic focus on three priority programs: EIK1001, a Toll-like receptor 7/8 (TLR7/8) agonist, EIK1003, a next-generation, highly selective PARP1 inhibitor, and EIK1005, a WRN helicase inhibitor</em><br/><br/></li><li style="text-align:left;"><em>Six abstracts accepted for the American Society of Clinical Oncology (ASCO) annual meeting highlighting new data from the company’s lead programs including new safety, tolerability, and efficacy data </em><br/><br/></li><li style="text-align:left;"><em>Publication of a manuscript in the Journal of Medicinal Chemistry on the use of single molecule tracking http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+Updates/26468713.html Mon, 11 May 2026 16:01:00 -0400 A.50216614 A.50216726 EIKN O.21612337 O.49773468 http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+Updates/26468713.html <ul><li style="text-align:left;"><em>Maintained strong financial position with $596 million in cash, cash equivalents and marketable securities as of March 31, 2026</em><br/><br/></li><li style="text-align:left;"><em>Continued execution across the oncology pipeline, with a strategic focus on three priority programs: EIK1001, a Toll-like receptor 7/8 (TLR7/8) agonist, EIK1003, a next-generation, highly selective PARP1 inhibitor, and EIK1005, a WRN helicase inhibitor</em><br/><br/></li><li style="text-align:left;"><em>Six abstracts accepted for the American Society of Clinical Oncology (ASCO) annual meeting highlighting new data from the company’s lead programs including new safety, tolerability, and efficacy data </em><br/><br/></li><li style="text-align:left;"><em>Publication of a manuscript in the Journal of Medicinal Chemistry on the use of single molecule tracking http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+Updates/26468713.html Mon, 11 May 2026 16:01:00 -0400 A.50216614 A.50216726 EIKN O.21612337 O.49773468 http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+Updates/26468713.html <ul><li style="text-align:left;"><em>Maintained strong financial position with $596 million in cash, cash equivalents and marketable securities as of March 31, 2026</em><br/><br/></li><li style="text-align:left;"><em>Continued execution across the oncology pipeline, with a strategic focus on three priority programs: EIK1001, a Toll-like receptor 7/8 (TLR7/8) agonist, EIK1003, a next-generation, highly selective PARP1 inhibitor, and EIK1005, a WRN helicase inhibitor</em><br/><br/></li><li style="text-align:left;"><em>Six abstracts accepted for the American Society of Clinical Oncology (ASCO) annual meeting highlighting new data from the company’s lead programs including new safety, tolerability, and efficacy data </em><br/><br/></li><li style="text-align:left;"><em>Publication of a manuscript in the Journal of Medicinal Chemistry on the use of single molecule tracking http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+Updates/26468713.html Mon, 11 May 2026 16:01:00 -0400 A.50216614 A.50216726 EIKN O.21612337 O.49773468 http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+Updates/26468713.html <ul><li style="text-align:left;"><em>Maintained strong financial position with $596 million in cash, cash equivalents and marketable securities as of March 31, 2026</em><br/><br/></li><li style="text-align:left;"><em>Continued execution across the oncology pipeline, with a strategic focus on three priority programs: EIK1001, a Toll-like receptor 7/8 (TLR7/8) agonist, EIK1003, a next-generation, highly selective PARP1 inhibitor, and EIK1005, a WRN helicase inhibitor</em><br/><br/></li><li style="text-align:left;"><em>Six abstracts accepted for the American Society of Clinical Oncology (ASCO) annual meeting highlighting new data from the company’s lead programs including new safety, tolerability, and efficacy data </em><br/><br/></li><li style="text-align:left;"><em>Publication of a manuscript in the Journal of Medicinal Chemistry on the use of single molecule tracking http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+Updates/26468713.html Mon, 11 May 2026 16:01:00 -0400 A.50216614 A.50216726 EIKN O.21612337 O.49773468 http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+Updates/26468713.html <ul><li style="text-align:left;"><em>Maintained strong financial position with $596 million in cash, cash equivalents and marketable securities as of March 31, 2026</em><br/><br/></li><li style="text-align:left;"><em>Continued execution across the oncology pipeline, with a strategic focus on three priority programs: EIK1001, a Toll-like receptor 7/8 (TLR7/8) agonist, EIK1003, a next-generation, highly selective PARP1 inhibitor, and EIK1005, a WRN helicase inhibitor</em><br/><br/></li><li style="text-align:left;"><em>Six abstracts accepted for the American Society of Clinical Oncology (ASCO) annual meeting highlighting new data from the company’s lead programs including new safety, tolerability, and efficacy data </em><br/><br/></li><li style="text-align:left;"><em>Publication of a manuscript in the Journal of Medicinal Chemistry on the use of single molecule tracking http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+Updates/26468713.html Mon, 11 May 2026 16:01:00 -0400 A.50216614 A.50216726 EIKN O.21612337 O.49773468 http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+Updates/26468713.html <ul><li style="text-align:left;"><em>Maintained strong financial position with $596 million in cash, cash equivalents and marketable securities as of March 31, 2026</em><br/><br/></li><li style="text-align:left;"><em>Continued execution across the oncology pipeline, with a strategic focus on three priority programs: EIK1001, a Toll-like receptor 7/8 (TLR7/8) agonist, EIK1003, a next-generation, highly selective PARP1 inhibitor, and EIK1005, a WRN helicase inhibitor</em><br/><br/></li><li style="text-align:left;"><em>Six abstracts accepted for the American Society of Clinical Oncology (ASCO) annual meeting highlighting new data from the company’s lead programs including new safety, tolerability, and efficacy data </em><br/><br/></li><li style="text-align:left;"><em>Publication of a manuscript in the Journal of Medicinal Chemistry on the use of single molecule tracking http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+Updates/26468713.html Mon, 11 May 2026 16:01:00 -0400 A.50216614 A.50216726 EIKN O.21612337 O.49773468 http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+Updates/26468713.html <ul><li style="text-align:left;"><em>Maintained strong financial position with $596 million in cash, cash equivalents and marketable securities as of March 31, 2026</em><br/><br/></li><li style="text-align:left;"><em>Continued execution across the oncology pipeline, with a strategic focus on three priority programs: EIK1001, a Toll-like receptor 7/8 (TLR7/8) agonist, EIK1003, a next-generation, highly selective PARP1 inhibitor, and EIK1005, a WRN helicase inhibitor</em><br/><br/></li><li style="text-align:left;"><em>Six abstracts accepted for the American Society of Clinical Oncology (ASCO) annual meeting highlighting new data from the company’s lead programs including new safety, tolerability, and efficacy data </em><br/><br/></li><li style="text-align:left;"><em>Publication of a manuscript in the Journal of Medicinal Chemistry on the use of single molecule tracking http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+Updates/26468713.html Mon, 11 May 2026 16:01:00 -0400 A.50216614 A.50216726 EIKN O.21612337 O.49773468 http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+Updates/26468713.html <ul><li style="text-align:left;"><em>Maintained strong financial position with $596 million in cash, cash equivalents and marketable securities as of March 31, 2026</em><br/><br/></li><li style="text-align:left;"><em>Continued execution across the oncology pipeline, with a strategic focus on three priority programs: EIK1001, a Toll-like receptor 7/8 (TLR7/8) agonist, EIK1003, a next-generation, highly selective PARP1 inhibitor, and EIK1005, a WRN helicase inhibitor</em><br/><br/></li><li style="text-align:left;"><em>Six abstracts accepted for the American Society of Clinical Oncology (ASCO) annual meeting highlighting new data from the company’s lead programs including new safety, tolerability, and efficacy data </em><br/><br/></li><li style="text-align:left;"><em>Publication of a manuscript in the Journal of Medicinal Chemistry on the use of single molecule tracking http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+Updates/26468713.html Mon, 11 May 2026 16:01:00 -0400 A.50216614 A.50216726 EIKN O.21612337 O.49773468 http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+Updates/26468713.html <ul><li style="text-align:left;"><em>Maintained strong financial position with $596 million in cash, cash equivalents and marketable securities as of March 31, 2026</em><br/><br/></li><li style="text-align:left;"><em>Continued execution across the oncology pipeline, with a strategic focus on three priority programs: EIK1001, a Toll-like receptor 7/8 (TLR7/8) agonist, EIK1003, a next-generation, highly selective PARP1 inhibitor, and EIK1005, a WRN helicase inhibitor</em><br/><br/></li><li style="text-align:left;"><em>Six abstracts accepted for the American Society of Clinical Oncology (ASCO) annual meeting highlighting new data from the company’s lead programs including new safety, tolerability, and efficacy data </em><br/><br/></li><li style="text-align:left;"><em>Publication of a manuscript in the Journal of Medicinal Chemistry on the use of single molecule tracking http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+Updates/26468713.html Mon, 11 May 2026 16:01:00 -0400 A.50216614 A.50216726 EIKN O.21612337 O.49773468 http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+Updates/26468713.html <ul><li style="text-align:left;"><em>Maintained strong financial position with $596 million in cash, cash equivalents and marketable securities as of March 31, 2026</em><br/><br/></li><li style="text-align:left;"><em>Continued execution across the oncology pipeline, with a strategic focus on three priority programs: EIK1001, a Toll-like receptor 7/8 (TLR7/8) agonist, EIK1003, a next-generation, highly selective PARP1 inhibitor, and EIK1005, a WRN helicase inhibitor</em><br/><br/></li><li style="text-align:left;"><em>Six abstracts accepted for the American Society of Clinical Oncology (ASCO) annual meeting highlighting new data from the company’s lead programs including new safety, tolerability, and efficacy data </em><br/><br/></li><li style="text-align:left;"><em>Publication of a manuscript in the Journal of Medicinal Chemistry on the use of single molecule tracking http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+Updates/26468713.html Mon, 11 May 2026 16:01:00 -0400 A.50216614 A.50216726 EIKN O.21612337 O.49773468 http://www.streetinsider.com/Analyst+Comments/Mizuho+stays+Outperform+rated+on+Eikon+Therapeutics+Inc.+%28EIKN%29+following+FY25+earnings+and+pipeline+update/26240159.html <p>Mizuho analyst Joseph Catanzaro reiterated an Outperform rating and $26.00 price target on Eikon Therapeutics Inc. (NASDAQ: EIKN)</p><p>The analyst commented, "EIKN reported FY25 EPS and provided a pipeline update, which follows our recent initiation of coverage (here). Guidance around the pipeline for 2026 was largely reiterated (new today was disclosure that Phase II/III study for EIK1001 in 1L melanoma has cleared its first safety review) with a number of updates expected in 2H26. Most notable will be updated Phase II data for EIK1001 in 1L NSCLC, which includes more patients (n=53 at ESMO 2025), longer follow-up and will provide insights http://www.streetinsider.com/Analyst+Comments/Mizuho+stays+Outperform+rated+on+Eikon+Therapeutics+Inc.+%28EIKN%29+following+FY25+earnings+and+pipeline+update/26240159.html Mon, 30 Mar 2026 15:02:35 -0400 EIKN